A short-term dosing Phase IIb study of INF904
Latest Information Update: 17 Nov 2024
At a glance
- Drugs INF 904 (Primary)
- Indications Autoimmune disorders; Inflammation
- Focus Therapeutic Use
Most Recent Events
- 08 Nov 2024 According to InflaRx media release, company plans to initiate phase IIb trial in late 2025.
- 05 Jun 2024 According to InflaRx media release, company plans to initiate phase IIb trial for Autoimmune disorders and Inflammation in 2025.
- 08 Jan 2024 New trial record